Top

Published in:

Open Access 01-01-2019 | Original Article

Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review

Authors: Katerina Dvorak, Amanda Higgins, John Palting, Michael Cohen, Patrick Brunhoeber

Published in: Pathology & Oncology Research | Issue 1/2019

Abstract

The major aim of this study was to evaluate the performance of anti-BRAF V600E (VE1) antibody in colorectal tumors with and without KRAS mutation. KRAS and BRAF are two major oncogenic drivers of colorectal cancer (CRC) that have been frequently described as mutually exclusive, thus the BRAF V600E mutation is not expected to be present in the cases with KRAS mutation. In addition, a review of 25 studies comparing immunohistochemistry (IHC) using the anti-BRAF V600E (VE1) antibody with BRAF V600E molecular testing in 4041 patient samples was included.

One-hundred and twenty cases with/without KRAS or BRAF mutations were acquired. The tissue were immunostained with anti-BRAF V600E (VE1) antibody with OptiView DAB IHC detection kit. The KRAS mutated cases with equivocal immunostaining were further evaluated by Sanger sequencing for BRAF V600E mutation. Thirty cases with BRAF V600E mutation showed unequivocal, diffuse, uniform, positive cytoplasmic staining and 30 cases with wild-type KRAS and BRAF showed negative staining with anti-BRAF V600E (VE1) antibody. Out of 60 cases with KRAS mutation, 56 cases (93.3%) were negative for BRAF V600E mutation by IHC. Four cases showed weak, equivocal, heterogeneous, cytoplasmic staining along with nuclear staining in 25–90% of tumor cells. These cases were confirmed to be negative for BRAF V600E mutation by Sanger sequencing. Overall, IHC with anti-BRAF V600E (VE1) antibody using recommended protocol with OptiView detection is optimal for detection of BRAF V600E mutation in CRC. Our data are consistent with previous reports indicating that KRAS and BRAF V600E mutation are mutually exclusive.

Adackapara CA, Sholl LM, Barletta JA et al (2013) Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 63:187–193CrossRefPubMed

Affolter K, Samowitz W, Tripp S et al (2013) BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes, chromosomes & cancer 52:748–752CrossRef

Bledsoe JR, Kamionek M, Mino-Kenudson M (2014) BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity. Am J Surg Pathol 38:1418–1428CrossRefPubMedPubMedCentral

Boulagnon C, Dudez O, Beaudoux O et al (2016) BRAFV600E Gene Mutation in Colonic Adenocarcinomas. Immunohistochemical Detection Using Tissue Microarray and Clinicopathologic Characteristics: An 86 Case Series. Appl Immunohistochem Mol Morphol 24:88–96CrossRefPubMed

Capper D, Preusser M, Habel A et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11–19CrossRefPubMed

Capper D, Berghoff AS, Magerle M et al (2012) Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 123:223–233CrossRefPubMed

Capper D, Voigt A, Bozukova G et al (2013) BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. International journal of cancer Journal international du cancer 133:1624–1630CrossRefPubMed

Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMed

Day F, Muranyi A, Singh S et al (2015) A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol 10:99–109CrossRefPubMed

10.

Douillard JY, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034CrossRefPubMed

11.

Dvorak K, Aggeler B, Palting J et al (2014) Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology 46:509–517CrossRefPubMedPubMedCentral

12.

Estrella JS, Tetzlaff MT, Bassett RL Jr et al (2015) Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. Mol Cancer Ther 14:2887–2895CrossRefPubMed

13.

Hang JF, Li AF, Chang SC et al (2016) Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test. Histopathology 69:54–62CrossRefPubMed

14.

Hartman DJ, Brand RE, Hu H et al (2013) Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach. Hum Pathol 44:2518–2528CrossRefPubMed

15.

Hernowo BS, Ariyanni F, Suryanti S et al (2014) Use of BRAF V600E as a molecular marker in aggressive colorectal cancer. Acta Med Indones 46:104–110PubMed

16.

Ilie MI, Long-Mira E, Hofman V et al (2014) BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. Pathology 46:311–315CrossRefPubMed

17.

Jin M, Hampel H, Zhou X et al (2013) BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome. Am J Clin Pathol 140:177–183CrossRefPubMed

18.

Koinuma K, Shitoh K, Miyakura Y et al (2004) Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 108:237–242CrossRefPubMed

19.

Kuan SF, Navina S, Cressman KL et al (2014) Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization. Hum Pathol 45:464–472CrossRefPubMed

20.

Lasota J, Kowalik A, Wasag B et al (2014) Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. Am J Surg Pathol 38:1235–1241CrossRefPubMedPubMedCentral

21.

Loes IM, Immervoll H, Angelsen JH et al (2015) Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. Tumour Biol 36:1003–1013CrossRefPubMed

22.

Marin C, Beauchet A, Capper D et al (2013) Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Arch Pathol Lab Med 138:71–75CrossRefPubMed

23.

Morkel M, Riemer P, Blaker H et al (2015) Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget 6:20785–20800CrossRefPubMedPubMedCentral

24.

Nolan S, Arnason T, Drucker A et al (2014) The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability. Appl Immunohistochem Mol Morphol 22:e8–e13CrossRefPubMed

25.

Oikonomou E, Koustas E, Goulielmaki M et al (2014) BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 5:11752–11777CrossRefPubMedPubMedCentral

26.

Pakneshan S, Salajegheh A, Smith RA et al (2013) Clinicopathological relevance of BRAF mutations in human cancer. Pathology 45:346–356CrossRefPubMed

27.

Parsons MT, Buchanan DD, Thompson B et al (2012) Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 49:151–157CrossRefPubMed

28.

Piton N, Borrini F, Bolognese A et al (2015) KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer? Gastroenterol Res Pract 2015:753903CrossRefPubMedPubMedCentral

29.

Qiu T, Lu H, Guo L et al (2015) Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. Sci Rep 5:9211CrossRefPubMedPubMedCentral

30.

Rajagopalan H, Bardelli A, Lengauer C et al (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934CrossRefPubMed

31.

Ren J, Li G, Ge J et al (2012) Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon rectum 55:913–923CrossRefPubMed

32.

Ritterhouse LL, Barletta JA (2015) BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol 32:400–408CrossRefPubMed

33.

Rossle M, Sigg M, Ruschoff JH et al (2013) Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. Virchows Arch 463:623–631CrossRefPubMed

34.

Roth RM, Hampel H, Arnold CA et al (2015) A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial. Am J Clin Pathol 143:336–343CrossRefPubMed

35.

Routhier CA, Mochel MC, Lynch K et al (2013) Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol 44:2563–2570CrossRefPubMed

36.

Sajanti S, Sirnio P, Vayrynen JP et al (2014) VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma. Virchows Arch 464:637–643CrossRefPubMed

37.

Schafroth C, Galvan JA, Centeno I et al (2015) VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer. Oncotarget 6:41453–41463CrossRefPubMedPubMedCentral

38.

Seppala TT, Bohm JP, Friman M et al (2015) Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer 112:1966–1975CrossRefPubMedPubMedCentral

39.

Sinicrope FA, Smyrk TC, Tougeron D et al (2013) Mutation-specific antibody detects mutant BRAF protein expression in human colon carcinomas. Cancer 119(15):2765–2770CrossRefPubMedPubMedCentral

40.

Taieb J, Le Malicot K, Shi Q et al (2017) Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. J Natl Cancer Inst 109. https://doi.org/10.1093/jnci/djw272

41.

Thiel A, Heinonen M, Kantonen J et al (2013) BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Archiv : an international journal of pathology 463:613–621CrossRef

42.

Thiel A, Heinonen M, Kantonen J et al (2013) BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch 463:613–621CrossRefPubMed

43.

Toon CW, Walsh MD, Chou A et al (2013) BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 37:1592–1602CrossRefPubMedPubMedCentral

44.

Toon CW, Chou A, DeSilva K et al (2014) BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 27:644–650CrossRef

45.

Vakiani E, Yaeger R, Brooke S et al (2015) Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms. Appl Immunohistochem Mol Morphol 23:438–443CrossRefPubMedPubMedCentral

46.

Yuan L, Chi Y, Chen W et al (2015) Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency. Int J Clin Exp Med 8:20988–21000PubMedPubMedCentral

Title: Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review
Authors: Katerina Dvorak
Amanda Higgins
John Palting
Michael Cohen
Patrick Brunhoeber
Publication date: 01-01-2019
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 1/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0344-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients

Proximal-Type Epithelioid Sarcoma in Skull Base: a Pathological Diagnosis Challenge with Other Intracranial Tumors

The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors

Multidetector Computed Tomographic Urography (MDCTU): Its Practical Role in Diagnosis of Upper Tract Urothelial Cancer in Patients 50 years and Older with Different Types of Hematuria

Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric Cancer

MiR-490-5p Inhibits Hepatocellular Carcinoma Cell Proliferation, Migration and Invasion by Directly Regulating ROBO1

Keynote webinar | Spotlight on antibody–drug conjugates in cancer